日本无限资源_福禄影院午夜伦_美国av毛片_亚洲自拍在线观看_激情亚洲一区国产精品_999久久久久

Higher doses of radiation don't improve survival in prostate cancer: study

Source: Xinhua| 2018-03-16 06:07:14|Editor: yan
Video PlayerClose

CHICAGO, March 15 (Xinhua) -- Compared with standard radiation treatment, higher doses of radiation do not improve survival for many patients with prostate cancer, a study led by researchers at Washington University School of Medicine in St. Louis shows.

The study included about 1,500 patients with intermediate-risk prostate cancer that most patients fall into. To be classified in this risk category, patients generally have PSA scores of 10-20 ng/ml and a Gleason score of seven.

Both treatment groups received external beam radiation. The standard group received a radiation dose of 70.2 gray delivered over 39 treatment visits. The investigational group received increasing doses up to 79.2 gray delivered over 44 visits. A gray is the standard measure of radiation a material has absorbed.

Of the 748 men receiving standard treatment, 75 percent were still alive after eight years of follow-up. Of the 751 men receiving the dose-escalation treatment, 76 percent were alive at the eight-year mark, a difference that is not statistically significant.

Over the course of the study, 51 patients died of prostate cancer, which is 3.4 percent of all patients enrolled. At the eight-year mark, the death rate due to prostate cancer for patients receiving standard treatment was four percent compared with two percent for patients receiving the escalating dose. These rates also were not statistically different.

While there was no difference in overall survival numbers, Jeff M. Michalski, first author and professor of radiation oncology of Washington University, pointed out some differences in side effects and in whether further treatment was needed later.

Patients in the standard dose group were more likely to undergo further therapies to control tumors that had grown larger or that had spread to another site in the body. While patients in the escalating dose group experienced more side effects, such as urinary irritation or rectal bleeding, sometimes years after treatment.

During the 10 years it took to enroll enough patients in the trial, at least six new therapies were approved for recurrent or metastatic prostate cancer, and these therapies have been shown to improve survival.

"If there is a difference between standard and escalating doses, it's hard to show it when the patients who later develop recurrent cancer can have their lives extended through the use of additional therapies," said Michalski.

The study, the first that is large enough to examine whether these improved measurements translate into longer survival for patients, is published Thursday in JAMA Oncology.

TOP STORIES
EDITOR’S CHOICE
MOST VIEWED
EXPLORE XINHUANET
010020070750000000000000011105521370422301
主站蜘蛛池模板: 亚洲精品一区二区三区蜜桃久 | 日本公妇乱淫免费视频一区三区 | 成人美女黄网站色大免费的 | 精品久久久久久中文字幕2017 | 日韩r级在线观看 | 亚洲无av在线中文字幕 | 亚洲国产天堂久久国产91 | 色综合.com | 国产福利无码一区二区在线 | 久久精品a一级国产免视看成人 | 日韩大片在线免费观看 | 亚洲欧洲国产日韩 | 最新国产网站 | 日韩精品一区二区亚洲AV | 国产一区二区片 | yy6080亚洲精品一区 | 视频二区国产 | xxxx天堂网上xxxx | 99热1| 欧美日韩观看 | 一本大道香一蕉久 | 国产在线高清视频无码不卡互動交流 | 国语一区| 欧美日韩一区二区三区在线视频 | a级黄色片免费看 | 爱av免费 | 欧美xxxx喷水 | 青青草视频在线观看视频 | 久久WWW免费人成人片 | 日本熟妇无码色视频在线观看 | 视频国产一区二区 | 亚洲AV无码不卡私人影院 | 日本美女中文字幕 | 袖珍幻女bbwxxxx | 免费日韩av | 天天躁夜夜躁狠狠躁婷婷 | 特级毛片A级毛片免费播放 婷婷久久久亚洲欧洲日产国码AV | 蜜臀亚洲AV无码之国产精品 | 激情人妻绿帽王八系列 | 男女午夜猛烈啪啦啦视频 | 91精品国产二区在线看大桥未久 |